GX 110

Drug Profile

GX 110

Alternative Names: GX-110; GX-110E; HB 110E; HB-110

Latest Information Update: 11 Feb 2016

Price : $50

At a glance

  • Originator Dong-A Pharmaceutical; Genexine
  • Developer Dong-A ST; Genexine
  • Class DNA vaccines; Hepatitis B vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - Hepatitis B

Highest Development Phases

  • No development reported Hepatitis B

Most Recent Events

  • 11 Feb 2016 No recent reports on development identified - Phase-II for Hepatitis B in South Korea (IM)
  • 31 Jul 2013 Genexine completes a phase II trial in Hepatitis B in South Korea (NCT01813487)
  • 30 Apr 2013 Genexine completes a phase I trial in Hepatitis B in South Korea (NCT01641536)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top